218 related articles for article (PubMed ID: 26228369)
1. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.
Peng J; Cao J; Yu T; Cai S; Li Z; Zhang X; Sun J
Saudi J Gastroenterol; 2015; 21(4):245-53. PubMed ID: 26228369
[TBL] [Abstract][Full Text] [Related]
2. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations].
Martín Mateos RM; Moreira Vicente VF; Tavío Hernández E; Cuño Roldán JL; Téllez Villajos L; Aicart Ramos M; Arribas Anta J; Zaera de la Fuente C; Albillos Martínez A
Gastroenterol Hepatol; 2015 May; 38(5):305-12. PubMed ID: 25636371
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
4. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
[TBL] [Abstract][Full Text] [Related]
6. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
7. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.
Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L
Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.
He D; Guo S; Chen W; Chen X; Yan G; Wang J; Li M; Zhu P; Huang H; Wang Y
BMC Infect Dis; 2013 Oct; 13():458. PubMed ID: 24090287
[TBL] [Abstract][Full Text] [Related]
9. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis.
Liu Y; Jia M; Wu S; Jiang W; Feng Y
Int J Infect Dis; 2019 Sep; 86():201-207. PubMed ID: 31394205
[TBL] [Abstract][Full Text] [Related]
10. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients.
Ge GH; Ye Y; Zhou XB; Chen L; He C; Wen DF; Tan YW
World J Gastroenterol; 2015 Jul; 21(28):8653-9. PubMed ID: 26229407
[TBL] [Abstract][Full Text] [Related]
12. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
[TBL] [Abstract][Full Text] [Related]
13. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B.
Papatheodoridi M; Papatheodoridis G
Cells; 2020 Feb; 9(2):. PubMed ID: 32093411
[TBL] [Abstract][Full Text] [Related]
14. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
[TBL] [Abstract][Full Text] [Related]
15. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Buster EH; Schalm SW; Janssen HL
Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Nucleos(t)ide Analogues Discontinuation Relapse: Hepatitis B Virus RNA versus Hepatitis B Surface Antigen.
Wu S; Li T; Liu F; Yin D; Zhang L; Wang L
J Coll Physicians Surg Pak; 2024 May; 34(5):545-550. PubMed ID: 38720214
[TBL] [Abstract][Full Text] [Related]
18. Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B.
Lee IC; Sun CK; Su CW; Wang YJ; Chang HC; Huang HC; Lee KC; Huang YS; Perng CL; Liu YH; Chua CS; Lin YM; Lin HC; Huang YH
Medicine (Baltimore); 2015 Aug; 94(32):e1341. PubMed ID: 26266383
[TBL] [Abstract][Full Text] [Related]
19. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
[TBL] [Abstract][Full Text] [Related]
20. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
